RS55636B1 - Metode za prepoznavanje rizika od poremećaja štitne žlezde - Google Patents

Metode za prepoznavanje rizika od poremećaja štitne žlezde

Info

Publication number
RS55636B1
RS55636B1 RS20170083A RSP20170083A RS55636B1 RS 55636 B1 RS55636 B1 RS 55636B1 RS 20170083 A RS20170083 A RS 20170083A RS P20170083 A RSP20170083 A RS P20170083A RS 55636 B1 RS55636 B1 RS 55636B1
Authority
RS
Serbia
Prior art keywords
thyroid
patient
antibody
treatment
risk
Prior art date
Application number
RS20170083A
Other languages
English (en)
Serbian (sr)
Inventor
David H Margolin
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of RS55636B1 publication Critical patent/RS55636B1/sr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/635—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70592—CD52
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/046—Thyroid disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
RS20170083A 2007-02-16 2008-02-15 Metode za prepoznavanje rizika od poremećaja štitne žlezde RS55636B1 (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90173207P 2007-02-16 2007-02-16
PCT/US2008/002047 WO2008103292A1 (en) 2007-02-16 2008-02-15 Method of identifying risk for thyroid disorder

Publications (1)

Publication Number Publication Date
RS55636B1 true RS55636B1 (sr) 2017-06-30

Family

ID=39434244

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20170083A RS55636B1 (sr) 2007-02-16 2008-02-15 Metode za prepoznavanje rizika od poremećaja štitne žlezde

Country Status (21)

Country Link
US (3) US20100136587A1 (https=)
EP (2) EP2538217A1 (https=)
JP (2) JP5662684B2 (https=)
CN (2) CN101657721B (https=)
AU (1) AU2008219097B2 (https=)
BR (1) BRPI0807601B8 (https=)
CA (1) CA2678199A1 (https=)
CY (1) CY1118663T1 (https=)
DK (1) DK2130044T3 (https=)
ES (1) ES2612558T3 (https=)
HR (1) HRP20170121T1 (https=)
HU (1) HUE031421T2 (https=)
IL (2) IL200314A (https=)
LT (1) LT2130044T (https=)
MX (1) MX2009008642A (https=)
PL (1) PL2130044T3 (https=)
PT (1) PT2130044T (https=)
RS (1) RS55636B1 (https=)
RU (1) RU2013120485A (https=)
SI (1) SI2130044T1 (https=)
WO (1) WO2008103292A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9498528B2 (en) * 2006-09-13 2016-11-22 Genzyme Corporation Treatment of multiple sclerosis (MS)
FR2934129B1 (fr) * 2008-07-24 2014-05-02 Oreal Procede de traitement cosmetique.
EP2335066B1 (en) * 2008-09-19 2016-12-28 University of Utah Research Foundation Methods for prediction of multiple sclerosis disease and therapy response
CN106257288A (zh) * 2016-08-15 2016-12-28 余洋 一种血清TPOAb IgG4水平检测方法
CN112312921A (zh) 2018-07-02 2021-02-02 美国西门子医学诊断股份有限公司 新型甲状腺过氧化物酶自身抗体免疫测定
KR102469743B1 (ko) 2020-06-10 2022-11-22 주식회사 타이로스코프 약물 복용에 따른 갑상선 기능 모니터링 방법, 이를 수행하는 모니터링 서버 및 사용자 단말
EP4001919A1 (en) * 2020-11-13 2022-05-25 Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal Predictive biomarkers of autoimmunity in patients treated with alemtuzumab
WO2024158259A1 (ko) * 2023-01-27 2024-08-02 주식회사 타이로스코프 대상에 대한 갑상선기능이상증의 예측방법 및 시스템

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5846534A (en) 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
GB9125768D0 (en) * 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
GB2265713A (en) * 1992-05-16 1993-10-06 R S R Limited Assay for autoantibodies against thyroglobulin or thyroid peroxidase
DE19710211C2 (de) * 1997-03-12 1999-12-16 Brahms Diagnostica Gmbh Verfahren zur Bestimmung von Schilddrüsen-Autoantikörpern
GB9823397D0 (en) * 1998-10-27 1998-12-23 Rsr Ltd Assays for thyroid autoantibodies
JP2008523785A (ja) * 2004-10-12 2008-07-10 カーランテック，インコーポレーテッド 神経変性、自己免疫脱髄、および糖尿病のウイルス病原に対する動物モデル系
US9498528B2 (en) 2006-09-13 2016-11-22 Genzyme Corporation Treatment of multiple sclerosis (MS)

Also Published As

Publication number Publication date
JP5662684B2 (ja) 2015-02-04
JP2014149313A (ja) 2014-08-21
RU2013120485A (ru) 2014-11-20
BRPI0807601A2 (pt) 2014-05-06
MX2009008642A (es) 2009-10-20
LT2130044T (lt) 2017-02-10
CN101657721A (zh) 2010-02-24
AU2008219097B2 (en) 2011-06-23
CY1118663T1 (el) 2017-07-12
CN108303546B (zh) 2023-01-03
SI2130044T1 (sl) 2017-03-31
IL242391A (en) 2017-09-28
IL200314A0 (en) 2010-04-29
US9664688B2 (en) 2017-05-30
PL2130044T3 (pl) 2017-04-28
US20130095507A1 (en) 2013-04-18
EP2130044A1 (en) 2009-12-09
EP2130044B1 (en) 2016-10-26
CN108303546A (zh) 2018-07-20
US20100136587A1 (en) 2010-06-03
BRPI0807601B1 (pt) 2021-02-23
HK1257419A1 (zh) 2019-10-18
US20170307629A1 (en) 2017-10-26
DK2130044T3 (en) 2017-02-06
BRPI0807601B8 (pt) 2021-07-27
JP2010519512A (ja) 2010-06-03
ES2612558T3 (es) 2017-05-17
HRP20170121T1 (hr) 2017-03-24
IL200314A (en) 2015-11-30
WO2008103292A1 (en) 2008-08-28
CA2678199A1 (en) 2008-08-28
US10648986B2 (en) 2020-05-12
AU2008219097A1 (en) 2008-08-28
EP2538217A1 (en) 2012-12-26
JP6058585B2 (ja) 2017-01-11
HUE031421T2 (hu) 2017-07-28
RU2009134313A (ru) 2011-03-27
CN101657721B (zh) 2018-02-23
PT2130044T (pt) 2017-02-03

Similar Documents

Publication Publication Date Title
US10648986B2 (en) Method of identifying risk for thyroid disorder
CN101223448B (zh) 来自自身免疫病受试者的生物学样品的预处理
Willicombe et al. Outcome of patients with preformed donor-specific antibodies following alemtuzumab induction and tacrolimus monotherapy
EP2350661B1 (en) Neurological autoimmune disorders
US9783600B2 (en) Apolipoprotein C3 (ApoCIII) antagonists and methods of their use to remove ApoCIII inhibition of lipoprotein lipase (LPL)
JPH09507578A (ja) インスリン受容体チロシンキナーゼインヒビターに対するアンタゴニスト
JP2001501598A (ja) 子癇前症および糖尿病の診断および処置に関する材料および方法
JP6203740B2 (ja) アルファ４ベータ７ヘテロ二量体特異抗体の投与
Kadlubowski et al. The lack of specificity of ophthalmic immunoglobulins in Graves’ disease
EP1181554A1 (en) Method for detecting deficient cellular membrane tightly bound magnesium for disease diagnoses
JP2002537307A (ja) 甲状腺機能亢進症の治療におけるブロッキング抗ｔｓｈレセプター抗体の使用およびかかる使用のためのモノクローナル抗体
JP2002528722A (ja) 自己抗体のためのアッセイ
Gauna et al. Immunological aspects of Graves’ disease patients in different clinical stages
US20230251272A1 (en) Amh and/or inhibin b as a biomarker for an effect of a treatment to improve male fertility
RU2575560C2 (ru) Способ выявления риска расстройства щитовидной железы
HK1180393A (en) Method of identifying risk for thyroid disorder
US20160137741A1 (en) Muscle Specific Tyrosine Kinase-Fluorophore Conjugate Compositions, Kits and Methods of Using
HK1257419B (en) Method of identifying risk for thyroid disorder
AU2010313318A1 (en) Use of immunoregulatory nk cell populations for predicting the efficacy of anti-il-2r antibodies in multiple sclerosis patients
Condon Improving Outcomes in Glomerulonephritis